BioSpace News Archive

First Quarter Net Loss from Continuing Operations of $72.7 Million, or $1.36 Per Share, Compared to the Prior Year First Quarter Net Loss of $99.3 Million, or $1.88 Per Share

Rite Aid Corporation announced that it has commenced an exchange offer to Eligible Holders for up to $750 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2023 for newly issued 8.000% Senior Secured Notes due 2026 and cash, upon the terms and subject to the conditions set forth in the offering memorandum and consent solicitation statement dated June 25, 2020.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical professionals, announced the successful completion of amendments and extensions of certain of its financing facilities, which enhances the Company’s liquidity and financial flexibility.

Edge Pharma has signed an agreement with ANI Pharmaceuticals to market the company’s FDA approved Vancomycin Hydrochloride for Oral Solution USP, a generic equivalent to Vancocin®.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced a presentation at the AACR Annual Meeting held from June 22nd-24th, 2020, illustrating a unique approach to creating drugs capable of reaching tumors hiding in organs where existing anticancer drugs cannot accumulate in therapeutic concentrations.

Tris Pharma, Inc., a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the launch of a new corporate website that better embodies the company’s evolving business model and strategic goals.

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020

Moderna, Inc. and Catalent, Inc. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.

Intensity Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced the publication of results from the Company’s nonclinical research in the International Journal of Molecular Sciences (IJ

AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds Reduction in fibrosis was observed from single AIV001 treatment post-wounding NEWPORT BEACH, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced completion of its first Phase 1/2a study evaluating AIV001 in dermal scarring. A total of 16 subjects who